Our Vision is to Cure Alzheimer’s Disease: Health Connexions and Recombinant Technologies Announce a Ground-Breaking Partnership to Accelerate Success in Alzheimer’s Disease

BOSTON--()--Realizing a potential cure for Alzheimer’s disease is the vision and goal of a new partnership between innovative biotechnology company Recombinant Technologies™ and life sciences research enabler and commercialization expert, Health Connexions™, the companies announced today.

This announcement follows successful proof-of-concept studies for Recombinant Technologies’ innovative AmyTrap™ drug candidates, which have been shown in preclinical experiments to trap and clear Alzheimer’s disease-causing β-amyloid plaques, thereby restoring memory by restoring the natural balance of beta-amyloid in the body.

With Alzheimer’s disease labelled a “looming epidemic” by governments and health organizations worldwide, Health Connexions™ CEO and President, Dawn Van Dam, says enabling development of a health solution is the priority for this ground-breaking partnership.

“A cure for Alzheimer’s disease – a debilitating, heartbreaking, and ultimately fatal disease – has yet to be realized; but innovations in medical science, such as Recombinant Technologies’ small molecule AmyTrap™ drug candidates, offer a potential health solution to this growing global, unmet medical need,” she said.

Health Connexions™ is committed to helping Recombinant Technologies complete studies for Alzheimer’s disease drug development. By working hand-in-hand with them to attract investors to fund additional development studies, this one-of-a-kind, promising and proprietary AmyTrap™ breakthrough technology can be fast-tracked through the development pipeline.

Inventor, Founder and CEO of Recombinant Technologies, Dr. Pazhani Sundaram, whose prior research efforts have produced marketable health products, says the proprietary AmyTrap™ drug candidates are innovations based on more than twelve years of research.

“Through a rigorous, peer-reviewed evaluation process by the National Institute on Aging, National Institutes of Health, Recombinant Technologies was previously granted funding to demonstrate the efficacy of its AmyTrap™ drug candidates in proof-of-concept model experiments,” he said. “Based on that success with these retro inverse peptide molecules, which provide a ‘trap’ for binding and clearing disease-causing beta-amyloid, patent protection was sought and was obtained in 2013 for the AmyTrap™ technology.”

Partnership enabling Alzheimer’s disease drug development

Recombinant Technologies now aims to complete Investigational New Drug (IND)-enabling, pre-clinical studies to progress the development of these innovative AmyTrap™ drug candidates.

“We are happy to partner with Health Connexions™ and leverage their expertise, making Recombinant Technologies’ promising, potential cure for Alzheimer’s disease well-known, and ready AmyTrap for further investment and development,” said Dr. Sundaram.

Health Connexions™ is working with Recombinant Technologies to coordinate the receipt of expressions of interest from biopharmaceutical companies, investment banks, funding bodies, and others interested in providing the capital to fund a possible cure for Alzheimer’s disease. With the number of people with Alzheimer’s disease expected to quadruple from over 26 million in 2006 to 106 million worldwide in 2050, for investors, this market holds an unprecedented potential return on investment.

Health Connexions:

The Health Connexions™ vision is to transform science into commercial success. Health Connexions helps clients in the life sciences and health care sectors by leveraging its extensive network and unique collaborative model in consulting, market research, technology evaluations and marketing communications services. Health Connexions also provides strategic advisory services for capital raising to fund new innovations, new opportunities, and the growth of established organizations. Visit www.healthconnexions.com.

Recombinant Technologies:

Recombinant Technologies is a specialized biotechnology company with world-leading expertise in retro inverse peptides and Alzheimer’s disease. It was founded in 1999 by Dr. Pazhani Sundaram to market novel biological reagents from Yale University research; Dr. Sundaram is the co-inventor of AmyTrap and already has one drug in the market, based on his research. . Recombinant Technologies is based in Cheshire, CT. Visit http://www.recombtech.com/index.php/alzheimer-s-drug-discovery-2.

Contacts

Dawn Van Dam
President & CEO
Health Connexions™
416-402-8274
dawn@healthconnexions.com

Release Summary

Recombinant Technologies, an innovative biotechnology company announces its partnership with Health Connexions, a life sciences research enabler and commercialization expert.

Contacts

Dawn Van Dam
President & CEO
Health Connexions™
416-402-8274
dawn@healthconnexions.com